Skip to main content
Premium Trial:

Request an Annual Quote

CeMines Relocates from Los Angeles to La Jolla

NEW YORK, June 22 (GenomeWeb News) - CeMines, which is developing its molecular fingerprinting technologies for early-stage diagnostics and therapeutics, has relocated from Los Angeles to an expanded facility in La Jolla, Calif., the company said today.


The new 9,000 square-foot facility in La Jolla, Calif., will enable the company to "build automated analysis systems for high-throughput and high-content screening," and to commercialize products, Roger Attick, president and chief executive officer of CeMines, said in a statement.


The company's research division was formerly located at the Ceders Sinai Medical Center in Los Angeles.


The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.